A team of researchers at the Indian Institute of Technology (IIT) Roorkee has introduced an advanced antibody discovery platform with the potential to revolutionize disease diagnostics and treatment. This platform includes an extensive single-domain antibody library, facilitating the swift identification of robust antibodies for various conditions like infectious diseases, cancer, and autoimmune disorders. The innovation aims to expedite healthcare responses by streamlining the antibody discovery process, especially crucial during health crises.
The initiative led by Prof. Rajesh Kumar from the Department of Biosciences and Bioengineering at IIT Roorkee emphasizes the importance of creating a diverse antibody discovery system within India. This development not only enhances the nation’s disease response capabilities but also accelerates the production of cost-effective diagnostics and treatments, benefiting vulnerable populations. Aligned with the vision of Atmanirbhar Bharat and Make in India, this research holds significance for low- and middle-income countries striving to improve healthcare accessibility.
In line with the national agenda to boost indigenous research and reduce dependence on imported medical solutions, the project underscores the necessity of fostering local research expertise and intellectual property creation. It complements governmental efforts to advance translational research, bolster pandemic readiness, and fortify the healthcare sector for long-term resilience. Prof. K. K. Pant, the Director of IIT Roorkee, highlighted the societal impact of merging fundamental research with practical applications and industry partnerships to address critical challenges effectively.
To expedite the implementation of these advancements, IIT Roorkee has forged a strategic collaboration between academia and industry partners to facilitate the transfer, expansion, and validation of antibody-based innovations. The institute’s partnership with IMGENEX India, formalized through a Memorandum of Understanding (MoU), aims to foster joint research endeavors, co-create advanced biologics, and enhance expertise in antibody engineering, diagnostics, therapeutics, and bioprocess development.
